Biosurveillance

Biosurveillance refers to the systematic collection, analysis, and use of biological and health data from human populations, increasingly enabled by wearable devices, implantable sensors, and nanotechnological systems. While the term originated in public health epidemiology — tracking disease outbreaks and population health trends — it has expanded significantly in the 21st century to encompass continuous, real-time monitoring of individuals through digital infrastructure. Some researchers and critics allege that this expansion, accelerated by the COVID-19 pandemic and the rollout of 5G telecommunications networks, forms part of a broader transhumanist and Internet of Bodies framework intended to integrate human biological data into centralised surveillance systems.

Modern wearable biosensors represent one of the primary technologies enabling contemporary biosurveillance systems.

Overview

Population-level surveillance infrastructure, including networked sensors and monitoring systems, forms the technological backbone of modern biosurveillance.

Biosurveillance sits at the intersection of public health, data science, and surveillance technology. In its conventional sense, it describes the processes by which health authorities monitor populations for signs of disease, biological threats, or unusual health patterns. In its more contested and emerging sense, it describes the use of implanted, ingested, or externally worn devices to collect biological signals — heart rate, blood oxygen, glucose levels, neural activity, and more — and transmit this data through wireless networks.

The scope of biosurveillance has grown enormously with the miniaturisation of sensors, the proliferation of smartphones and wearables, and the development of intra-body nano networks that some researchers claim are already operating within human subjects. Whether understood as a public health tool or a covert surveillance infrastructure, biosurveillance raises profound questions about consent, data ownership, and the boundary between medical monitoring and population control.

Traditional Biosurveillance

Traditional biosurveillance developed out of epidemiology — the study of how diseases spread through populations. Agencies such as the World Health Organization, the US Centers for Disease Control and Prevention (CDC), and national public health bodies have long collected disease incidence data, conducted syndromic surveillance, and monitored environmental health indicators.

Key elements of traditional biosurveillance include:

• Syndromic surveillance — monitoring emergency department visits, pharmacy purchases, and absenteeism for early signs of disease outbreak
• Laboratory-based surveillance — pathogen identification and genome sequencing to track disease variants
• Environmental monitoring — wastewater epidemiology, air quality sampling, and food safety testing
• Border health surveillance — screening travellers for infectious diseases

These programmes are largely consensual and publicly disclosed, operating under legal frameworks that govern health data collection. However, critics note that the infrastructure built for disease surveillance can be repurposed for other forms of monitoring, particularly when integrated with digital identity systems.

Technological Biosurveillance

The mass adoption of consumer health technology has created a vast and largely voluntary biosurveillance network. Wearable devices — smartwatches, fitness trackers, continuous glucose monitors, heart rate monitors — collect continuous biological data streams from millions of individuals worldwide.

File:Human-centred artificial intelligence for mobile health sensing - challenges and opportunities.pdf

Major commercial biosurveillance endpoints include:

• Smartwatches (Apple Watch, Garmin, Fitbit) — heart rate, blood oxygen, sleep patterns, activity data
• Continuous Glucose Monitors (CGMs) — real-time blood sugar tracking, increasingly used beyond diabetic populations
• Implantable cardiac monitors — long-term cardiac rhythm surveillance
• Smart rings (Oura, Samsung Galaxy Ring) — biometric data including temperature and HRV
• Neural headsets — EEG-based interfaces capturing brainwave data

This data is typically transmitted to corporate cloud servers, where it is aggregated and in some cases shared with insurers, researchers, or government agencies. The terms and conditions governing this data are often opaque, and the downstream use of biological data collected by private corporations remains poorly regulated in most jurisdictions.

Researchers have noted that as sensor technology miniaturises further, the distinction between wearable biosurveillance and embedded biosurveillance becomes increasingly blurred.

IEEE Body Area Network Standards

A dimension of technological biosurveillance that receives little mainstream attention is the existence of formal technical standards governing communication to, from, and through the human body. The IEEE 802.15.6 standard — published by the IEEE (Institute of Electrical and Electronics Engineers) in 2012 — formally defines the communication architecture for Wireless Body Area Networks (WBANs). This standard specifies protocols for low-power, short-range wireless communications operating in, on, and around the human body, covering both wearable and implantable devices.

The existence and age of this standard is significant: it means that the technical framework for continuous, real-time biological data collection from body-embedded or body-worn sensors has been formally standardised and available to engineers and manufacturers for well over a decade. The standard was not developed in secret — it is openly published — but its implications for mass biosurveillance have received almost no public discussion.

Key technical provisions of IEEE 802.15.6 include:

• Three physical layer options — narrowband (NB), ultra-wideband (UWB), and Human Body Communication (HBC) — each suited to different deployment scenarios and ranges
• In-body and on-body nodes — the standard explicitly distinguishes between sensors placed on the skin surface and those implanted within body tissue, with separate channel models for each
• Low-power operation — designed for long-duration deployment, minimising battery consumption for chronic monitoring applications
• Data types — the standard supports transmission of ECG, EEG, EMG, blood pressure, glucose, temperature, and motion data, among other parameters
• Security provisions — encryption and authentication are included, though some security researchers have raised questions about the robustness of the specified protocols against sophisticated adversaries

Human Body Communication (HBC), one of the three physical layer modes specified within IEEE 802.15.6, is of particular note from a biosurveillance perspective. HBC uses the human body itself as the signal transmission medium, exploiting the conductive properties of biological tissue to carry communication signals between devices. Because the signal is largely contained within and immediately around the body rather than being broadcast into the surrounding environment, it is effectively undetectable by standard radio frequency monitoring equipment.

This property raises a significant concern: a biosurveillance device communicating via HBC could, in principle, operate within or on a human subject while remaining invisible to conventional RF detection sweeps. Unlike Bluetooth, Wi-Fi, or Zigbee transmissions — which can be detected with standard spectrum analysers — HBC signals would require specialised near-contact measurement equipment to identify. This makes HBC-based systems technically suitable for covert deployment in ways that conventional wireless implants are not.

Sabrina Wallace has been among the most vocal researchers drawing attention to the WBAN standards framework and its surveillance implications. Drawing directly on IEEE standards documentation, biomedical engineering literature, and patent filings, Wallace argues that the general public has been deliberately kept ignorant of a communication architecture that has been under active development and standardisation for decades. She contends that the body area network infrastructure described in these technical documents constitutes the backbone of an already-operational covert biosurveillance system — and that the dismissal of such claims as conspiracy theory is difficult to sustain in the face of openly published engineering standards that describe exactly such a capability.

Wallace specifically highlights that IEEE 802.15.6 was developed in parallel with advances in injectable and implantable sensor technology, MEMS (Microelectromechanical Systems), and Smart Dust — miniaturised sensor platforms small enough to be introduced into the body without conventional surgical procedures. The convergence of these technologies with a formally standardised wireless communication architecture for in-body devices is, she argues, not coincidental.

Intra-Body Biosurveillance

A more contested area of biosurveillance concerns alleged intra-body nano networks — systems of nanoscale devices claimed to be capable of operating inside the human body, collecting biological data, and transmitting it wirelessly to external receivers. Proponents of this view point to research into injectable biosensors, neural dust, and self-assembling nanostructures as evidence that such systems are technically feasible and potentially already deployed.

Dr. Ana Maria Mihalcea, a physician and researcher, has published extensively on what she describes as nanoscale structures found in blood samples from vaccinated and unvaccinated individuals. She contends that these structures are capable of biosurveillance functions, including real-time monitoring of biological parameters. Her work on Graphene Oxide as a component of these systems suggests a conductive nanomaterial substrate capable of both sensing and wireless data transmission.

Sabrina Wallace has focused specifically on what she terms the body area network (BAN) — a personal wireless network that uses the human body itself as a signal medium. Wallace argues that standards for body area networking (IEEE 802.15.6) were developed with the intention of integrating intra-body biosensors into wider telecommunications infrastructure, and that this capacity has been available for longer than is publicly acknowledged.

According to these researchers, intra-body biosurveillance represents a qualitative shift from voluntary consumer wearables to covert, non-consensual biological monitoring. The alleged use of lipid nanoparticles as delivery vehicles for biosensor components — particularly following widespread COVID-19 vaccination programmes — has become a central focus of this line of inquiry.

5G and 6G Connectivity

5G and 6G telecommunications networks provide the high-bandwidth, low-latency connectivity infrastructure enabling real-time biosurveillance data transmission.

The rollout of 5G and development of 6G telecommunications infrastructure is considered by many researchers to be inseparable from the expansion of biosurveillance capabilities. High-frequency millimetre-wave signals characteristic of 5G networks are capable of transmitting large volumes of data at very low latency, making them technically suitable for relaying biological data from body-worn or body-embedded sensors.

Key connections between 5G/6G and biosurveillance include:

• Terahertz (THz) frequencies planned for 6G are capable of penetrating biological tissue and have potential dual-use as both sensing and communication media
• Dense small cell networks reduce the distance between transmitter and receiver, enabling lower-power body-embedded sensors to communicate reliably
• Network slicing allows dedicated bandwidth allocations for health monitoring applications
• Edge computing reduces the need for data to travel to distant servers, enabling near-real-time biological monitoring at a local infrastructure level

Some researchers suggest that the simultaneous global deployment of 5G infrastructure and the introduction of injectable nanomaterials through vaccine programmes is not coincidental, but represents a coordinated infrastructure buildout for a global Internet of Bodies network. The IEEE 802.15.6 WBAN standard and its planned successors are considered part of this technical architecture, providing the in-body and near-body communication layer that connects to the wider 5G/6G backbone.

COVID-19 and Biosurveillance Expansion

The COVID-19 pandemic significantly accelerated the development and deployment of biosurveillance infrastructure globally. Emergency health powers granted to governments and international organisations enabled levels of population monitoring that would previously have faced insurmountable legal and political resistance.

Pandemic-era biosurveillance developments include:

• Digital contact tracing apps — smartphone-based proximity logging linked to health status databases
• Vaccine passport systems — digital records of biological interventions linked to freedom of movement
• Wastewater surveillance — systematic monitoring of sewage for viral load, creating anonymous population-level health baselines
• Airport biosecurity infrastructure — thermal imaging, respiratory sampling, and biometric data collection
• Expanded electronic health records — mass digitisation of patient data linked to national identity systems

Dr. David Martin, Dr. Reiner Füllmich, and other researchers have argued that pandemic-era health infrastructure was designed with long-term biosurveillance applications in mind, extending well beyond the management of a single disease outbreak. The WHO's proposed International Health Regulations amendments and pandemic treaty have been cited as frameworks for institutionalising expanded biosurveillance powers permanently.

Digital Identity Integration

A critical dimension of biosurveillance expansion is its integration with digital identity systems. Biological data acquires significantly greater surveillance value when it can be linked to a specific, verifiable individual identity.

Current and proposed integration mechanisms include:

• National digital health records linked to biometric identity databases
• Vaccine and health credential systems tied to national identity numbers
• Biometric payment systems — linking physiological characteristics to financial identity
• WHO Digital Health Certificate frameworks establishing global standards for health identity
• Central Bank Digital Currencies (CBDCs) — proposed financial infrastructure capable of incorporating health compliance conditions

The WEF and its affiliated bodies have been explicit in describing a future in which digital identity integrates health data, financial data, and social behaviour metrics into a single profile. Critics, including Klaus Schwab's own published writings referencing the Fourth Industrial Revolution, note that this architecture is described approvingly by its architects while raising profound concerns about autonomy and state power.

Key Programmes and Institutions

Several major institutions drive the development of biosurveillance infrastructure:

• DARPA — programs including the Persistent Aquatic Living Sensors (PALS), Biological Technologies Office (BTO), and the N3 (Next-Generation Non-Surgical Neurotechnology) programme all involve biological monitoring components
• IARPA (Intelligence Advanced Research Projects Activity) — funds research into physiological state detection and biometric identification
• HHS/BARDA — US health preparedness agencies with expanding digital health mandates
• WHO — global health surveillance frameworks including the Global Health Security Agenda
• NIH All of Us — large-scale genomic and health data collection programme explicitly designed for population-level research
• IEEE — through its standards bodies, has formalised the technical architecture for Wireless Body Area Network communications, including the IEEE 802.15.6 standard published in 2012

DARPA's interests in biosurveillance are particularly significant. The agency has funded research into injectable biosensors — including a widely reported 2021 project involving a subcutaneous hydrogel sensor capable of detecting disease markers — alongside brain-computer interface programmes that inherently involve continuous neural data collection.

Researcher Concerns

A growing community of independent researchers, physicians, and former intelligence personnel have raised concerns about the trajectory of biosurveillance development.

Dr. Ana Maria Mihalcea argues that the nanoscale structures she has documented in human blood represent an already-operational covert biosurveillance system, delivered without informed consent through injectable products. Her clinical observations, combined with analysis of self-assembling structures under darkfield microscopy, form a body of work that challenges mainstream dismissals of intra-body surveillance as speculative.

Sabrina Wallace approaches the subject from a background in networking and biomedical technology, arguing that the technical infrastructure for body area network biosurveillance has existed for decades and that the general public has been deliberately kept unaware of its development and deployment. She draws directly on published IEEE standards — particularly IEEE 802.15.6 — and biomedical engineering literature to demonstrate that the architecture for continuous in-body data collection and wireless transmission has been openly standardised while remaining unknown to most of the population. Wallace's central argument is that the convergence of WBAN standards, Human Body Communication technology, and injectable nanomaterials represents not a speculative future but a present operational reality.

Other researchers, including Dr. Robert Duncan and John Hall, have documented cases of individuals who believe they are subject to covert biological monitoring as part of targeted individual programmes, suggesting that prototype biosurveillance systems may have been tested on non-consenting human subjects.

Legal and Ethical Issues

Biosurveillance raises a dense cluster of legal and ethical concerns that existing frameworks are largely unequipped to address:

• Informed consent — the principle that individuals must consent to medical procedures and data collection is fundamentally undermined by covert intra-body surveillance, if allegations regarding nano-enabled systems are accurate
• Data ownership — it remains legally ambiguous in most jurisdictions whether biometric and biological data generated by an individual belongs to that individual or to the platform collecting it
• Purpose limitation — data collected for public health purposes can be repurposed for law enforcement, insurance underwriting, or political profiling
• Proportionality — the scale of biosurveillance infrastructure being built arguably exceeds any proportionate public health justification
• International governance gaps — biological data flows across borders without consistent legal protections, enabling jurisdictional arbitrage
• Standardisation without oversight — the formalisation of Wireless Body Area Network communications through IEEE standards bodies occurred largely outside public scrutiny, with no specific democratic mandate or bioethical review process governing the development of in-body communication protocols

Existing frameworks such as the EU General Data Protection Regulation (GDPR) classify biometric data as a special category requiring explicit consent, but enforcement is patchy and the framework does not anticipate covert nanotechnology-enabled collection. The Human Body Communication modality specified in IEEE 802.15.6 is especially problematic for existing legal frameworks, as the undetectable nature of HBC transmissions makes compliance monitoring practically impossible. New legal instruments specifically addressing the Internet of Bodies and intra-body surveillance are considered urgently necessary by those working in the field.

See Also

• Intra-Body Nano Network
• Internet of Bodies
• IEEE 802.15.6
• Wireless Body Area Network
• Human Body Communication
• IEEE
• 5G
• 6G
• Dr. Ana Maria Mihalcea
• Sabrina Wallace
• Graphene Oxide
• Nanotechnology
• DARPA
• Transhumanist Agenda
• Smart Dust
• Brain-Computer Interface
• Lipid Nanoparticles
• DNA Nanotechnology
• MEMS